628 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit http://www.zacks.com/stock/news/553102/thermo-fisher-closes-api-site-buyout-fortifies-pharma-unit?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-553102 Oct 07, 2019 - Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
Novo Nordisk Focuses on Pipeline Development Amid Competition http://www.zacks.com/stock/news/552953/novo-nordisk-focuses-on-pipeline-development-amid-competition?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-552953 Oct 07, 2019 - Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly http://www.zacks.com/stock/news/548879/the-zacks-analyst-blog-highlights-bank-of-america-home-depot-philip-morris-nextera-and-eli-lilly?cid=CS-ZC-FT-press_releases-548879 Oct 04, 2019 - The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly
Top Research Reports for Bank of America, Home Depot & Philip Morris http://www.zacks.com/research-daily/547512/top-research-reports-for-bank-of-america-home-depot-philip-morris?cid=CS-ZC-FT-research_daily-547512 Oct 03, 2019 - Top Research Reports for Bank of America, Home Depot & Philip Morris
Why Lilly (LLY) Could Beat Earnings Estimates Again http://www.zacks.com/stock/news/547471/why-lilly-lly-could-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-547471 Oct 03, 2019 - Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novartis Reports Additional Data on Spondylitis Drug Cosentyx http://www.zacks.com/stock/news/547460/novartis-reports-additional-data-on-spondylitis-drug-cosentyx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-547460 Oct 03, 2019 - Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
Novartis (NVS) Announces Data on Asthma Drugs & Kisqali http://www.zacks.com/stock/news/545899/novartis-nvs-announces-data-on-asthma-drugs-kisqali?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-545899 Oct 02, 2019 - Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.
Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study http://www.zacks.com/stock/news/542832/pfizers-jak1-inhibitor-meets-all-goals-in-2nd-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542832 Sep 30, 2019 - Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.
IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA http://www.zacks.com/stock/news/539102/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-539102 Sep 27, 2019 - IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
How Big Can This $8 Billion-Plus Diabetes Drug Class Get? https://www.fool.com/investing/2019/09/26/how-big-can-this-8-billion-diabetes-drug-class-get.aspx?source=iedfolrf0000001 Sep 26, 2019 - GLP-1 drugs keep getting easier to take.

Pages: 1234567...63

<Page 2>